je.st
news
First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily Dosing Regimen of ISENTRESS (raltegravir)
2014-06-05 23:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. ONCEMRK Study Globally Enrolling Treatment-Nave Adults with HIV-1 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the companys global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-nave HIV-1-infected adults. Language: English Contact: MerckMedia Contacts:Caroline Lappetito, 267-305-7639Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
program
trial
phase
Category:Biotechnology and Pharmaceuticals